ADMA Biologics Inc 2026年季度报告

FORM 10-Q ☒(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the quarterly period endedMarch 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the transition period from ________ to ________Commission file number 001-36728ADMA BIOLOGICS, INC. (Exact name of registrant as specified in its charter) Delaware56-2590442(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 465 State Route 17,Ramsey,New Jersey07446(Address of principal executive offices)(Zip Code) (201) 478-5552(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☐Emerging growth company☐ Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2026, there were 231,772,715 shares of the issuer’s common stock outstanding. ADMA BIOLOGICS, INC. AND SUBSIDIARIES INDEX PART I FINANCIAL INFORMATION Item 1.Financial StatementsCondensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20251Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026and 20252Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three MonthsEnded March 31, 2026 and 20253Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026and 20254Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.20Item 3.Quantitative and Qualitative Disclosures About Market Risk.30Item 4.Controls and Procedures.30PART II OTHER INFORMATION31Item 1.Legal Proceedings.31Item 1A.Risk Factors.31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.62Item 3.Defaults Upon Senior Securities.62Item 4.Mine Safety Disclosures.62Item 5.Other Information.62Item 6.Exhibits.62SIGNATURES64 This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as “ASCENIV™,” “Nabi-HB®” and “BIVIGAM®,” which are protected under applicable intellectual property laws and are the property of ADMA Biologics,Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appearwithout the®,™orSMsymbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullestextent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. Wedo not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should notbe construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains certain “forward-looking statements” within the meaning of Section 27A of theSecurities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the“Exchange Act”), and such forward-looking statements involve risks and uncertainties. These forward-looking statements include, butare not limited to, statements about our plans, objectives, representations and contentions that are not historical facts and typically areidentified by use of terms such as “may,” “shoul